Bicara Therapeutics reports Q3 net loss of $36.3M, gets FDA Breakthrough Therapy Designation for ficerafusp alfa

Bicara Therapeutics Inc.

2025-Q3 EPS reported -$1.84

Net loss $36.3M in Q3 2025 vs $17.5M in Q3 2024; R&D expenses rose to $33.0M from $15.9M.
Cash, equivalents, investments $407.6M as of Sept 30, 2025; expected to fund operations into H1 2029.
FDA granted Breakthrough Therapy Designation for ficerafusp alfa + pembrolizumab in 1L HPV-negative R/M HNSCC.
Phase 1b data for 750mg weekly dose of ficerafusp alfa + pembrolizumab expected at ESMO Asia 2025.
Expanded management team: Jenna Cohen (Chief Corp Affairs), Tanya Green (Chief Dev Officer), Bill Schelman (VP).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.